Article | March 14, 2022

Outsourcing Process Development: Key Considerations For Biopharma Companies

Source: Cytiva
GettyImages-1201263001-lab-team

A wide range of new opportunities in global healthcare have been created by a record level of investments across the biopharma industry. "Venture-capital funding, initial public offerings, and secondary offerings by already-public companies led to $88 billion in new equity in 2020, with most going toward emerging biopharma companies," according to the Drug, Chemical & Associated Technologies Association, data from investment firm Jefferies Financial Group Inc.1 This will likely result in a flurry of collaborations with contract development and manufacturing organizations (CDMOs) to help fill expertise and resource gaps within these developing companies.

Whether you are just entering the field or responding to the influx of competition, you must know how to vet potential providers, especially for process development services. This critical step is a key factor in determining your drug program’s overall success.

A panel of experts with experienced and diverse perspectives discussed this topic during an online event titled Best Practices for Outsourcing Process Development, where four themes surfaced that may help drive the best outcomes with your process development service provider.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: